Boeing Drops 11% After Q3 Print as Analysts Slash Targets

BA has had a brutal week, falling 11.7% to $168.18, the kind of move that forces a reassessment of where the recovery story actually stands.

The Q3 earnings report landed on October 27, and the market's verdict was immediate. The stock is now down 15% over the past month, trading well below where it started the year. More telling is the contrast with peers: GE added 3.2% on the day, RTX dropped just 1.5%, and SARO barely moved, finishing the week up 4.6%. SAF on the Paris exchange is also down sharply this week, falling 12.2%, the one peer that matched Boeing's pain, likely reflecting shared commercial aerospace exposure. But the rest of the sector held firm. Boeing's selloff is specific, not systemic.

The analyst reaction has been swift and one-directional. Every firm that has moved today has cut its price target, and the cuts are large. Barclays lowered to $250 from $300 while holding Overweight. Wells Fargo trimmed to $210 from $250, also maintaining Overweight. TD Cowen came down to $210 from $240, keeping Buy. Baird cut to $230 from $300. Morgan Stanley, already the most cautious voice on the Street, lowered again to $195 from $225 at Equal-Weight. The mean target now sits at $245, which implies significant distance from the current price. But the direction of travel is what matters: every analyst who has moved in the past two weeks has moved down. The consensus rating remains constructive overall, with most firms still carrying Outperform or Buy equivalents, yet target compression has been relentless. The bull case, centred on a $715 billion backlog, 8% revenue growth in Q2, and the first positive free cash flow in years at $631 million, remains intact on paper. The bear case points to NOPAT still in negative territory and return on capital that has not yet earned its cost.

Factor scores add nuance to the picture. EPS surprise ranks in the 94th percentile and 90-day EPS momentum ranks in the 96th, meaning the company has been beating estimates and analysts have been revising numbers upward over the medium term. That sits awkwardly against a 12th-percentile score on forward EPS growth, where the 12-month consensus still points to declining earnings. The analyst recommendation differential ranks in the 97th percentile, reflecting how much better Street sentiment is relative to other stocks, even after all the cuts. Earnings yield scores in the 18th percentile, a reminder that the valuation is pricing in a full recovery that has not yet materialised. The P/E multiple fell sharply this week, dropping roughly 9.6 points to 59x, and EV/EBITDA slipped to 21.5x.

Positioning in the lending market offers no signal about short-seller conviction. Short interest is just under 2% of the free float, down roughly 4% on the week, and borrow availability is extraordinarily loose at over 4,600%. That means there are roughly 46 shares available to borrow for every one currently lent out. Cost to borrow is 0.40%, near the low end of its recent range. The short score has drifted lower through the week to 30.7, also consistent with declining short-seller interest. None of this suggests organised short pressure. The selling this week looks like long holders reducing exposure, not a short thesis playing out. Options positioning confirms the caution without amplifying it: the put/call ratio is 0.82, slightly above its 20-day average of 0.81 but only 0.4 standard deviations above the mean, well within normal range for this name.

On the ownership register, Capital Research and Management added nearly 10 million shares in the most recent period, bringing their stake to just over 5%. BlackRock and Vanguard remain the largest holders at 7.7% and 7.1% respectively, both adding modestly. There is no 13D activist on the register. The institutional base remains stable for now, though the next quarterly reporting cycle will be the first real test of whether large holders reduced exposure on the Q3 print.

The next earnings event is pencilled in for January 27, 2027, ninety-one days away. Between now and then, the question is whether Q3 results were a one-off disappointment or confirmation that the recovery timeline is stretching further than the Street's still-elevated targets imply. Every analyst who has moved has moved down, the stock is trading at a level not seen in recent months, and the gap to even the most cautious targets is now wider than it was before the print.